L Number	Hits	Search Text	DB	Time stamp
-	449	topotecan	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/07/18 09:30
-	26	topotecan same liposom$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/07/15 11:57
-	1534	camptothecin	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/07/17 09:00
-	71	camptothecin same liposom$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/07/17 09:26
-	17	(topotecan and camptothecin) same liposom$	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/07/17 09:36
-	5	(topotecan and camptothecin) same liposom$ and sphingomyelin and cholesterol	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/07/17 09:57
-	3	((topotecan or camptothecin) same liposom$) and sphingomyelin and cholesterol and ionophore	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/07/17 10:04
-	2	((topotecan or camptothecin) same liposom$) and sphingomyelin and cholesterol and ionophore and topotecan and camptothecin	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/07/18 09:34
-	10	"5891468"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/07/18 09:32
-	19	"5552156"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/07/18 09:33
-	2	(liposom$) and sphingomyelin and cholesterol and ionophore and topotecan and camptothecin	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2002/07/18 09:34

09702165

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1619cto

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Jan 25	BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3	Jan 29	FSTA has been reloaded and moves to weekly updates
NEWS 4	Feb 01	DKILIT now produced by FIZ Karlsruhe and has a new update frequency
NEWS 5	Feb 19	Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 6	Mar 08	Gene Names now available in BIOSIS
NEWS 7	Mar 22	TOXLIT no longer available
NEWS 8	Mar 22	TRCTHERMO no longer available
NEWS 9	Mar 28	US Provisional Priorities searched with P in CA/CAplus and USPATFULL
NEWS 10	Mar 28	LIPINSKI/CALC added for property searching in REGISTRY
NEWS 11	Apr 02	PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 12	Apr 08	"Ask CAS" for self-help around the clock
NEWS 13	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 14	Apr 09	ZDB will be removed from STN
NEWS 15	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 16	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 17	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 18	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 19	Jun 03	New e-mail delivery for search results now available
NEWS 20	Jun 10	MEDLINE Reload
NEWS 21	Jun 10	PCTFULL has been reloaded
NEWS 22	Jul 02	FOREGE no longer contains STANDARDS file segment

NEWS EXPRESS	February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

09702165

FILE 'HOME' ENTERED AT 14:47:13 ON 18 JUL 2002

=> file medline, caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 14:47:22 ON 18 JUL 2002

FILE 'CAPLUS' ENTERED AT 14:47:22 ON 18 JUL 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

=> camptothecin
L1 6159 CAMPTOTHECIN

=> liposmom? and l1
L2 0 LIPOSMOM? AND L1

=> liposmom?
L3 0 LIPOSMOM?

=> liposom?
L4 63645 LIPOSOM?

=> l4 and l1
L5 125 L4 AND L1

=> l5 and sphingomyelin
L6 7 L5 AND SPHINGOMYELIN

=> l6 and topotecan
L7 3 L6 AND TOPOTECAN

=> dis l7 ibib abs 1-3

L7 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:31220 CAPLUS
DOCUMENT NUMBER: 136:90962
TITLE: Improved **liposomal camptothecins** and uses thereof
INVENTOR(S): Madden, Thomas D.; Semple, Sean C.
PATENT ASSIGNEE(S): Inex Pharmaceuticals Corporation, Can.
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002078	A2	20020110	WO 2001-CA981	20010629

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001070413	A5	20020114	AU 2001-70413		20010629
PRIORITY APPLN. INFO.:			US 2000-215556P	P	20000630
			US 2001-264616P	P	20010126
			WO 2001-CA981	W	20010629

AB This invention relates to improved **liposomal** **camptothecin** compns. and methods of using such compns. for treating neoplasia and for inhibiting angiogenesis. The compns. and methods are useful for modulating the plasma circulation half-life of an active agent. **Topotecan** (I) was encapsulated in **sphingomyelin**:cholesterol (55:45, mol/mol) **liposomes** using Mg-A-2318 ionophore method. The initial drug-to-lipid ratio was 0.1 (wt./wt.) and drug loading was typically 95-100%. The therapeutic index of the **liposomes** contg. I was 18 fold the free I in human breast cancer model MX-1.

L7 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:	2002:31219 CAPLUS
DOCUMENT NUMBER:	136:90961
TITLE:	**Liposomal** antineoplastic drugs and uses thereof
INVENTOR(S):	Madden, Thomas D.; Semple, Sean C.; Ahkong, Quet F.
PATENT ASSIGNEE(S):	Inex Pharmaceuticals Corporation, Can.
SOURCE:	PCT Int. Appl., 47 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	2
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002077	A2	20020110	WO 2001-CA925	20010629

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001070385	A5	20020114	AU 2001-70385		20010629
PRIORITY APPLN. INFO.:			US 2000-215556P	P	20000630
			US 2001-264616P	P	20010126
			WO 2001-CA925	W	20010629

AB This invention relates to **liposomal** antineoplastic agents (e.g., **camptothecin**) compns. and methods of using such compns. for treating neoplasia and for inhibiting angiogenesis. The compns. and methods are useful for modulating the plasma circulation half-life of an active agent. **Topotecan** (I) was encapsulated in **sphingomyelin**:cholesterol (55:45, mol/mol) **liposomes** using Mg-A-2318 ionophore method. The initial drug-to-lipid ratio was 0.1 (wt./wt.) and drug loading was typically 95-100%. The therapeutic index of the **liposomes** contg. I was 18 fold the free I in human breast

cancer model MX-1.

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:277830 CAPLUS
DOCUMENT NUMBER: 132:313695
TITLE: **Liposome**-entrapped topoisomerase inhibitors
INVENTOR(S): Slater, James Lloyd; Colbern, Gail T.; Working, Peter K.
PATENT ASSIGNEE(S): Alza Corporation, USA
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000023052	A1	20000427	WO 1999-US24228	19991015
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1121102	A1	20010808	EP 1999-954971	19991015
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9914601	A	20011023	BR 1999-14601	19991015
US 6355268	B1	20020312	US 1999-419189	19991015
NO 2001001844	A	20010410	NO 2001-1844	20010410

PRIORITY APPLN. INFO.: US 1998-104671P P 19981016
WO 1999-US24228 W 19991015

AB A compn. for the treatment of tumor contg. a therapeutically ED of a topoisomerase I inhibitor or topoisomerase I/II inhibitor is described. The compn. includes **liposomes** having an outer surface and an inner surface defining aq. **liposome** compartment, and being composed of a vesicle-forming lipid and of a vesicle-forming lipid derivatized with a hydrophilic polymer to form a coating of hydrophilic polymer chains on both the inner and outer surfaces of the **liposomes**. Entrapped in the **liposomes** is the topoisomerase inhibitor at a concn. of at least about 0.10 .mu.M drug per .mu.N lipid. A topoisomerase I inhibitor is selected from the group consisting of **camptothecin** and derivs. thereof.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

09702165

=> liposom? and cholesterol
L8 10812 LIPOSOM? AND CHOLESTEROL

=> l8 and topotecan
L9 11 L8 AND TOPOTECAN

=> l9 and ionophore
L10 4 L9 AND IONOPHORE

=> dis l10 ibib abs

L10 ANSWER 1 OF 4 MEDLINE
ACCESSION NUMBER: 2000393094 MEDLINE
DOCUMENT NUMBER: 20365399 PubMed ID: 10910044
TITLE: **Liposomal** encapsulation of **topotecan** enhances anticancer efficacy in murine and human xenograft models.
AUTHOR: Tardi P; Choice E; Masin D; Redelmeier T; Bally M; Madden T D
CORPORATE SOURCE: Inex Pharmaceuticals Corporation, Burnaby, British Columbia, Canada.
SOURCE: CANCER RESEARCH, (2000 Jul 1) 60 (13) 3389-93. Journal code: 2984705R. ISSN: 0008-5472.
PUB. COUNTRY: United States
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200008
ENTRY DATE: Entered STN: 20000824
Last Updated on STN: 20000824
Entered Medline: 20000817

AB **Topotecan** was encapsulated in sphingomyelin/**cholesterol** **liposomes** using an **ionophore**-generated proton gradient. After i.v. injection, **liposomal topotecan** was eliminated from the plasma much more slowly than free drug, resulting in a 400-fold increase in plasma area under the curve. Further, high-performance liquid chromatography analysis of plasma samples demonstrated that **topotecan** was protected from hydrolysis within the **liposomal** carrier with >80% of the drug remaining as the active, lactone species up to 24 h. The improved pharmacokinetics observed with **liposomal topotecan** correlated with increased efficacy in both murine and human tumor models. In the L1210 ascitic tumor model, optimal doses of **liposomal topotecan** resulted in a 60-day survival rate of 60-80%, whereas in a L1210 liver metastasis model, 100% long-term survival (>60 days) was achieved. In contrast, long-term survivors were rarely seen after treatment with free **topotecan**. Further, in a human breast carcinoma model (MDA 435/LCC6), **liposomal topotecan** provided greatly improved increase in life span relative to the free drug. These results suggest that **liposomal** encapsulation can significantly enhance the therapeutic activity of **topotecan**.

=> dis l10 ibib abs 1-20

L10 ANSWER 1 OF 4 MEDLINE
ACCESSION NUMBER: 2000393094 MEDLINE
DOCUMENT NUMBER: 20365399 PubMed ID: 10910044
TITLE: **Liposomal** encapsulation of **topotecan**

enhances anticancer efficacy in murine and human xenograft models.

AUTHOR: Tardi P; Choice E; Masin D; Redelmeier T; Bally M; Madden T D

CORPORATE SOURCE: Inex Pharmaceuticals Corporation, Burnaby, British Columbia, Canada.

SOURCE: CANCER RESEARCH, (2000 Jul 1) 60 (13) 3389-93.
Journal code: 2984705R. ISSN: 0008-5472.

PUB. COUNTRY: United States
Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200008

ENTRY DATE: Entered STN: 20000824
Last Updated on STN: 20000824
Entered Medline: 20000817

AB **Topotecan** was encapsulated in sphingomyelin/**cholesterol liposomes** using an **ionophore**-generated proton gradient. After i.v. injection, **liposomal topotecan** was eliminated from the plasma much more slowly than free drug, resulting in a 400-fold increase in plasma area under the curve. Further, high-performance liquid chromatography analysis of plasma samples demonstrated that **topotecan** was protected from hydrolysis within the **liposomal** carrier with >80% of the drug remaining as the active, lactone species up to 24 h. The improved pharmacokinetics observed with **liposomal topotecan** correlated with increased efficacy in both murine and human tumor models. In the L1210 ascitic tumor model, optimal doses of **liposomal topotecan** resulted in a 60-day survival rate of 60-80%, whereas in a L1210 liver metastasis model, 100% long-term survival (>60 days) was achieved. In contrast, long-term survivors were rarely seen after treatment with free **topotecan**. Further, in a human breast carcinoma model (MDA 435/LCC6), **liposomal topotecan** provided greatly improved increase in life span relative to the free drug. These results suggest that **liposomal** encapsulation can significantly enhance the therapeutic activity of **topotecan**.

L10 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:31220 CAPLUS
DOCUMENT NUMBER: 136:90962

TITLE: Improved **liposomal** camptothecins and uses thereof

INVENTOR(S): Madden, Thomas D.; Semple, Sean C.

PATENT ASSIGNEE(S): Inex Pharmaceuticals Corporation, Can.

SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002078	A2	20020110	WO 2001-CA981	20010629

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001070413	A5	20020114	AU 2001-70413		20010629
PRIORITY APPLN. INFO.:			US 2000-215556P	P	20000630
			US 2001-264616P	P	20010126
			WO 2001-CA981	W	20010629

AB This invention relates to improved **liposomal** camptothecin compns. and methods of using such compns. for treating neoplasia and for inhibiting angiogenesis. The compns. and methods are useful for modulating the plasma circulation half-life of an active agent. **Topotecan** (I) was encapsulated in sphingomyelin: **cholesterol** (55:45, mol/mol) **liposomes** using Mg-A-2318 **ionophore** method. The initial drug-to-lipid ratio was 0.1 (wt./wt.) and drug loading was typically 95-100%. The therapeutic index of the **liposomes** contg. I was 18 fold the free I in human breast cancer model MX-1.

L10 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:	2002:31219 CAPLUS
DOCUMENT NUMBER:	136:90961
TITLE:	**Liposomal** antineoplastic drugs and uses thereof
INVENTOR(S):	Madden, Thomas D.; Semple, Sean C.; Ahkong, Quet F.
PATENT ASSIGNEE(S):	Inex Pharmaceuticals Corporation, Can.
SOURCE:	PCT Int. Appl., 47 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	2
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002077	A2	20020110	WO 2001-CA925	20010629

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001070385	A5	20020114	AU 2001-70385		20010629
PRIORITY APPLN. INFO.:			US 2000-215556P	P	20000630
			US 2001-264616P	P	20010126
			WO 2001-CA925	W	20010629

AB This invention relates to **liposomal** antineoplastic agents (e.g., camptothecin) compns. and methods of using such compns. for treating neoplasia and for inhibiting angiogenesis. The compns. and methods are useful for modulating the plasma circulation half-life of an active agent. **Topotecan** (I) was encapsulated in sphingomyelin: **cholesterol** (55:45, mol/mol) **liposomes** using Mg-A-2318 **ionophore** method. The initial drug-to-lipid ratio was 0.1 (wt./wt.) and drug loading was typically 95-100%. The therapeutic index of the **liposomes** contg. I was 18 fold the free I in human breast cancer model MX-1.

L10 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2002 ACS

09702165

ACCESSION NUMBER: 2000:494205 CAPLUS
DOCUMENT NUMBER: 133:212986
TITLE: **Liposomal** encapsulation of **topotecan** enhances anticancer efficacy in murine and human xenograft models
AUTHOR(S): Tardi, Paul; Choice, Edward; Masin, Dana; Redelmeier, Thomas; Bally, Marcel; Madden, Thomas D.
CORPORATE SOURCE: Department of Advanced Therapeutics, British Columbia Cancer Agency, Vancouver, BC, V5Z 4E3, Can.
SOURCE: Cancer Research (2000), 60(13), 3389-3393
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB **Topotecan** was encapsulated in sphingomyelin/**cholesterol** **liposomes** using an **ionophore**-generated proton gradient. After i.v. injection, **liposomal topotecan** was eliminated from the plasma much more slowly than free drug, resulting in a 400-fold increase in plasma area under the curve. Further, high-performance liq. chromatog. anal. of plasma samples demonstrated that **topotecan** was protected from hydrolysis within the **liposomal** carrier with >80% of the drug remaining as the active, lactone species up to 24 h. The improved pharmacokinetics obsd. with **liposomal topotecan** correlated with increased efficacy in both murine and human tumor models. In the L1210 ascitic tumor model, optimal doses of **liposomal topotecan** resulted in a 60-day survival rate of 60-80%, whereas in a L1210 liver metastasis model, 100% long-term survival (>60 days) was achieved. In contrast, long-term survivors were rarely seen after treatment with free **topotecan**. Further, in a human breast carcinoma model (MDA 435/LCC6), **liposomal topotecan** provided greatly improved increase in life span relative to the free drug. These results suggest that **liposomal** encapsulation can significantly enhance the therapeutic activity of **topotecan**.

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>